TABLE 2.
Trials of C1 INH in transplantation listed in clinicaltrials.gova
| Title | Phase | NCT Number | Type | Sponsor | Status |
|---|---|---|---|---|---|
| C1 INH Preoperative and post-kidney transplant to prevent DGF and IRI | I | 02134314 | R, PC, DB | Cedars-Sinai Medical Center, Los Angeles, CA | Recruiting |
| Safety and tolerability of Berinert (C1 inhibitor) therapy to prevent AMR in HLA sensitized kidney transplant recipients | I | 01134510 | R, PC, DB | Cedars-Sinai Medical Center | Completed67 |
| Recombinant human C1 INH for the treatment of early AMR in renal transplantation | II | 01035593 | R, OL | Shire, Lexington, MA | Withdrawnb |
| A pilot study to evaluate the use of C1 INH (human) in patients with acute (kidney) AMR | II | 01147302 | R, PC, DB | Shire, Lexington, MA | Completed68 |
| Combined drug approach to prevent IRI during transplantation of livers | I | 01886443 | SB | Universitaire Ziekenhuisen Leuven, Belgium | Completed |
| Combined drug approach to prevent IRI during transplantation of livers (CAPITL) | II | 02251041 | R, SB | Universitaire Ziekenhuisen Leuven, Belgium | Recruiting |
| Cinryze as a donor pretreatment strategy in kidney recipients of KDPI>85% organs | I | 02435732 | R, PC, | University of Wisconsin Madison, Wl | Not yet recruiting |
a
No trials are listed in EUdraCT which are not listed here.
b
Sponsor’s comment: “Withdrawn due to Improvements in Clinical Practice (which) Have Reduced The Apparent Incidence of AMR.”
R indicates randomized; PC, placebo controlled; DB, double blinded; SB, single blinded (subject); OL, open label.